Skip to content
Peptigraph home

KLOW vs GLOW: What the Research Shows

KLOW and GLOW side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Four-peptide blendNot FDA approved · unstudied blendKLOWUnapproved blend of GHK-Cu, BPC-157, TB-500 and KPV; an FDA Drugs@FDA search for its component GHK-Cu returned no matches, so no approved product was found.[12]Healing & recoveryPre-mixed blendThree-peptide blendNot FDA approved · unstudied blendGLOWUnapproved blend of GHK-Cu, BPC-157 and TB-500; an FDA Drugs@FDA search for its component GHK-Cu returned no matches, so no approved product was found.[12]Healing & recoveryPre-mixed blend
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider KLOW if…

  • you want the added KPV component, but note its evidence is mouse and cell work only (no human trial found): KPV-treated mice recovered earlier and regained more body weight in DSS colitis.[13]

Consider GLOW if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

What they have in common

  • Klow is prohibited by WADA at all times, in and out of competition (a blend containing BPC-157)[1]
  • Glow is prohibited by WADA at all times, in and out of competition (a blend containing BPC-157)[1]
Neither is FDA approved for any use in people. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 3 of 12 fields where the two differ. Also called, Category, FDA status, PCAC vote, Jul 2026, WADA, Anti-doping detection, Half-life, Evidence strength, Typical study doses are the same or both unknown.

FieldKLOWGLOW
ClassFour-peptide blendThree-peptide blend
Human studies we summarised15 human (9 randomized or controlled) of 65 summarised, across ingredients15 human (9 randomized or controlled) of 56 summarised, across ingredients
Vial sizes sold80 mg50 mg, 70 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

The whole difference is one ingredient: KPV

GLOW and KLOW share GHK-Cu, BPC-157 and TB-500; what KLOW adds is KPV, and KPV is the least-studied of the four in people.[14]

The KPV literature is mouse colitis and peritonitis experiments, plus cell and skin-sample work; a mouse study found oral KPV lowered colitis incidence.[15]

Even the delivery question is open: KPV in a skin-permeation test did not cross human skin by simple diffusion, an ex vivo result that says nothing about injection.[16]

For the three components the two blends have in common, the one experiment that combined two of them found no extra benefit over either one alone, in rat Achilles tendons.[17]

The 'glow' in the name points at skin, where GHK-Cu is the only component with human trials, and those are small topical studies.[18]

What the extra ingredient changes in practice

KPV has no published stability guidance for a reconstituted vial; the only study is a stress test that identified a breakdown product under acid, alkali and peroxide.[19]

Neither blend escapes the anti-doping list, because TB-500 appears in both.[1]

FDA's regulatory page treats TB-500 as having no human exposure data, which applies equally to both blends.[14]

Because KLOW carries a fourth peptide, any adverse event cannot be pinned on a single ingredient; BPC-157's own pilot of intravenous infusion in two people reported no side effects, but that is far too small to compare blends.[20]

Common questions

What is the difference between KLOW and GLOW peptide?

KLOW adds KPV to the GHK-Cu, BPC-157 and TB-500 base that GLOW has; FDA reports no human exposure data for KPV.[14]

Is KLOW stronger than GLOW?

Nothing in the literature measures strength of either blend; the nearest experiment found two of the shared ingredients together gave no added benefit over one in rats.[17]

Which is better for skin, KLOW or GLOW?

The only skin evidence among the ingredients is for GHK-Cu, which both blends contain; KPV's skin data are cell and ex vivo skin tests.[18]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
  3. 3Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
  4. 4Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
  5. 5Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
  6. 6Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  7. 7Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
  8. 8A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
  9. 9Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
  10. 10Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
  11. 11PubMed search: (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab])) AND (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12Drugs@FDA (openFDA) search: active ingredient "GHK-Cu"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  13. 13Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
  14. 14Official web pageOfficial web page · web page
  15. 15PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
  16. 16Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.Journal of pharmaceutical sciences · 2017PMID 28343991Accessed 2 Oct 2026
  17. 17Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  18. 18Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.Archives of facial plastic surgery · 2006PMID 16847171Accessed 2 Oct 2026
  19. 19Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.Biomedical chromatography : BMC · 2015PMID 25298219Accessed 2 Oct 2026
  20. 20Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026

Found an error? Report a correction.